Alkermes: 7 Different Insiders Have Sold Shares This Month

| About: Alkermes plc (ALKS)

In this article, I will feature one biotech that has seen intensive insider selling during the last 30 days. Intensive insider selling can be defined by the following three criteria:

  1. The stock was sold by three or more insiders within one month.
  2. The stock was not purchased by any insiders in the month of intensive selling.
  3. At least two sellers decreased their holdings by more than 10%.

Alkermes (NASDAQ:ALKS) has a diversified portfolio of more than 20 commercial drug products and a substantial clinical pipeline of product candidates that address central nervous system disorders such as addiction, schizophrenia and depression.

Insider selling during the last 30 days

Here is a table of Alkermes' insider-trading activity during the last 30 days by insider.

Name Title Trade Date Shares Sold Rule 10b5-1 Current Ownership Decrease In Ownership
Floyd Bloom Director Dec 26 20,000 Yes 110,281 shares 15.4%
Gordon Pugh SVP Dec 20 22,500 Yes 68,301 shares 24.8%
Elliot Ehrich SVP Dec 16-18 60,854 Yes 16,579 shares + 1,748 options 76.9%
James Frates CFO Dec 11-17 67,874 Yes 89,514 shares 43.1%
Robert Breyer Director Dec 2 5,000 Yes 53,756 shares + 400 options 8.5%
Paul Mitchell Director Dec 2 1,500 Yes 8,000 shares + 11,000 options 7.3%
James Botkin SVP Dec 4 11,000 Yes 2,509 shares + 56,000 options 15.8%

There have been 188,728 shares sold by insiders during the last 30 days. All these shares were sold pursuant to a Rule 10b5-1 plan.

SEC Rule 10b5-1 is a regulation enacted by the United States Securities and Exchange Commission (SEC) in 2000. The SEC states that Rule 10b5-1 was enacted in order to resolve an unsettled issue over the definition of insider trading, which is prohibited by SEC Rule 10b-5. After Rule 10b5-1 was enacted, the SEC staff publicly took the position that canceling a planned trade made under the safe harbor does not constitute insider trading, even if the person was aware of the inside information when canceling the trade. This staff interpretation raises the possibility that executives can exploit this safe harbor by entering into 10b5-1 trading plans before they have inside information while retaining the option to later cancel those plans based on inside information.

For example, a CEO of a company could call a broker on January 1 and enter into a plan to sell a particular quantity of shares of his company's stock on March 1, find out terrible news about his company on February 1 that will not become public until April 1, and then go forward with the March 1 sale anyway, saving himself from losing money when the bad news becomes public. Under the terms of Rule 10b5-1(b) this is insider trading because the CEO "was aware" of the inside information when he made the trade. But he can assert an affirmative defense under Rule 10b5-1(c), because he planned the trade before he learned the inside information.

In general, it is a safer way for an insider to sell shares pursuant to a Rule 10b5-1 trading plan than without it.

Insider selling by calendar month

Here is a table of Alkermes' insider-trading activity by calendar month.

Month Insider selling / shares Insider buying / shares
December 2013 188,728 0
November 2013 51,071 0
October 2013 25,218 0
September 2013 159,933 0
August 2013 242,750 0
July 2013 345,980 0
June 2013 65,489 0
May 2013 68,172 0
April 2013 89,500 0
March 2013 93,999 0
February 2013 95,000 0
January 2013 490,091 0

There have been 1,915,931 shares sold, and there have been zero shares purchased by insiders this year.


Alkermes reported the fiscal 2014 second-quarter, which ended September 30, financial results on October 31 with the following highlights:

Revenue $139.8 million
GAAP Net loss $7.8 million
Cash $395.2 million
Debt $365.9 million


Alkermes' guidance for the nine-month period ending December 31, 2013 is as follows:

Revenue $395-$425 million
GAAP net loss $0-$25 million
Non-GAAP net income $85-$105 million

Pipeline and upcoming milestones

Alkermes has more than 20 commercial products and seven product candidates in the clinical stage pipeline.

(Source: November presentation)

Alkermes has completed enrollment in the Aripiprazole Lauroxil multinational Phase 3 program and expects to report top-line data in the first half of 2014.

(Source: November presentation)


Alkermes' competitors include Eli Lilly and Company (NYSE:LLY) with Zyprexa Relprevv, and Forest Laboratories (NYSE:FRX) with Campral. Here is a table comparing these companies.

Market Cap: 5.58B 55.36B 16.06B
Employees: 1,230 38,350 5,800
Qtrly Rev Growth (yoy): 0.13 0.06 0.14
Revenue: 577.76M 23.26B 3.21B
Gross Margin: 0.68 0.79 0.79
EBITDA: 153.86M 7.26B 148.81M
Operating Margin: 0.12 0.25 -0.01
Net Income: 18.83M 4.78B -14.90M
EPS: 0.14 4.37 -0.06
P/E: 297.81 11.73 N/A
PEG (5 yr expected): N/A N/A 1.01
P/S: 9.73 2.37 4.97

Alkermes has the highest P/S ratio among these three companies.

Here is a table of these competitors' insider-trading activities this year.

Company Insider buying / shares Insider selling / shares
LLY 0 122,646
FRX 0 59,197

Only Alkermes has seen intensive insider selling during the last 30 days.


There have been seven different insiders selling Alkermes, and there have not been any insiders buying Alkermes during the last 30 days. Five of these seven insiders decreased their holdings by more than 10%. Alkermes has an insider ownership of 0.70%.

There are five analyst buy ratings, three neutral ratings, and two sell ratings with an average price target of $36.17. Before entering short Alkermes, I would like to get a bearish confirmation from the Point and Figure chart. The three main reasons for the proposed short entry are bearish analyst price targets, relatively high P/S ratio, and the intensive insider-selling activity.

Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

About this article:

Tagged: , , , Drug Delivery & Accessories
Want to share your opinion on this article? Add a comment.
Disagree with this article? .
To report a factual error in this article, click here